About Us

Many screening platforms have emerged in recent years in Quebec. These platforms are generating an increasing number of candidates for the discovery of new drugs. Unfortunately, their clinical effectiveness is often not sufficient to make them into drugs. A good candidate must have optimal biopharmaceutical properties such as solubility, permeability, and stability, in addition to presenting adequate pharmacokinetic, metabolic, and toxicity profiles. Evaluating biopharmaceutical properties during the drug discovery phase allows for the selection of the best candidates, optimization of their properties, and ultimately conducting preclinical trials to increase the chances of success in the clinical phase.

To your disposal!

Our expertise in pharmaceutical research, both in industrial and academic, allows us to:

  • Assist our clients in identifying their needs and designing appropriate formulation and ADME-Tox experiments;
  • Provide support in solving problems related to formulation and ADME-Tox;
  • Generate high-quality results compliant with industry practices.

    • Our Team

    The biopharmacy platform was established in 2010 to address the need in research described above. It provides services in preformulation, formulation, and ADME-Tox for both academic and industrial laboratories. Our team consists of:

  • Pr Grégoire Leclair, B. Pharm, Ph. D., Director
  • Pr V. Gaëlle Roullin, Ph. D., Associate Director
  • Mihaela Friciu, Senior Research Advisor
  • Ouafa Benzima, Research Agent
  • Martin Jutras, Research Advisor
  • Louiza Mahrouche, Research Advisor
  • Maria Luise Neuper, Financial Management Agent
  • Isabelle St-Jean, Research Advisor

    • This content has been updated on 19 March 2024 at 14 h 47 min.